Psychedelics for treating psychiatric disorders: Are they safe?
Current Psychiatry. 2022 December;21(12):14-22 | doi: 10.12788/cp.0309
December 1, 2022|Current Psychiatry
Author and Disclosure Information
Though generally well-tolerated, these agents have been associated with a range of adverse effects.
Bottom Line
In clinical trials for psychiatric disorders, psychedelics have been associated with a range of cognitive, psychiatric, and psychoactive adverse effects but generally have been well-tolerated, with a low incidence of serious adverse effects.
Related Resources
- American Psychiatric Association. Position Statement on the Use of Psychedelic and Empathogenic Agents for Mental Health Conditions. Updated July 2022. Accessed October 24, 2022. https://www.psychiatry.org/getattachment/d5c13619-ca1f-491f-a7a8-b7141c800904/Position-Use-of-Psychedelic-Empathogenic-Agents.pdf
- Johns Hopkins Center for Psychedelic & Consciousness Research. https://hopkinspsychedelic.org/
- Multidisciplinary Association for Psychedelic Studies (MAPS). https://maps.org/
Drug Brand Names
Esketamine • Spravato
Ketamine • Ketalar
Venlafaxine • Effexor
